# A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Source: https://onco.cc/trials/nct06497985/  
OnCo record `nct06497985` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tucidinostat, Sintilimab, Bevacizumab in colorectal cancer, run by Chipscreen Biosciences, Ltd., now recruiting.

## Summary

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients is a phase 3 interventional study registered as NCT06497985 by Chipscreen Biosciences, Ltd., with 430 participants planned, started 2024-12-06 and due to reach its primary completion in 2028-05-31. Interventions recorded: Tucidinostat, Sintilimab, Bevacizumab, Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06497985
- Phase: 3
- Setting: A Randomised, Open-label, Multicenter Phase III Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients Who Failed at Least Second-line Standard Therapies
- Sponsor: Chipscreen Biosciences, Ltd.
- Enrolled: 430

## Sources

- ClinicalTrials.gov NCT06497985: https://clinicaltrials.gov/study/NCT06497985

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- companies: [Chipscreen Biosciences](https://onco.cc/companies/chipscreen/)

---
JSON: https://onco.cc/api/v1/entities/nct06497985.json